title: Aqueous stability of recombinant human thrombopoietin as a function of processing schemes.
abstract: Preformulation studies conducted with recombinant human thrombopoietin (rhTPO), a 332 amino acid glycoprotein which stimulates platelet production, show distinctions in degradation profiles as a function of processing schemes. The stability-limiting degradation pathways change as a function of purification stage and method and are dependent upon the presence of contaminating protease. The stability-limiting degradation pathway of affinity-purified and in-process rhTPO preparations is primarily attributed to proteolysis initiated by a protease present as a fermentation contaminant. The proteolysis increases with increasing pH as a function of temperature. The degradation profiles for these preparations show that bioactivity initially increases and then decreases with increasing pH as a function of temperature. This is consistent with proteolysis to active forms which ultimately undergo degradation to less active forms. Similar studies conducted with rhTPO preparations purified by a combination of more conventional chromatographic steps show different stability-limiting degradation pathways and a different pH-stability profile when compared to affinity purified or in-process preparations. In this case, degradation is accompanied by decreases in activity under all conditions, consistent with the conversion to less active forms. These results illustrate the importance of preformulation and stability characterization of protein pharmaceuticals in support of both process and formulation development. Issues related to storage and handling of inprocess preparations differ from those with formulated product since the stability-limiting degradation pathways change as a function of purification stage.
authors.affiliation: Biopharmaceuticals Division, ZymoGenetics Corporation, Seattle, WA 98102, USA.
authors.forename: R I
authors.initials: RI
authors.lastname: Senderoff
authors.forename: K M
authors.initials: KM
authors.lastname: Kontor
authors.forename: J K
authors.initials: JK
authors.lastname: Heffernan
authors.forename: H J
authors.initials: HJ
authors.lastname: Clarke
authors.forename: L K
authors.initials: LK
authors.lastname: Garrison
authors.forename: L
authors.initials: L
authors.lastname: Kreilgaard
authors.forename: G W
authors.initials: GW
authors.lastname: Lasser
authors.forename: G B
authors.initials: GB
authors.lastname: Rosenberg
mesh_terms: D000818:Animals; D002460:Cell Line; D006224:Cricetinae; D004355:Drug Stability; D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D011994:Recombinant Proteins / Q000737:chemistry; D013926:Thrombopoietin / Q000737:chemistry*
chemical_list: D011994:Recombinant Proteins; D013926:Thrombopoietin